Author: Tom Wilemon
Feb. 20, 2020—New therapies that re-engineer patients’ T-cells to target cancer and advances in stem cell transplantations that make it easier for patients to be matched with donors are among the topics at an upcoming symposium.
Feb. 13, 2020—An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.
Feb. 6, 2020—Josh Ferris was sitting in a hunting blind on Nov. 15, 2018, the first day of deer season in Michigan and the one-year anniversary of his stem cell donation, when he received an email from Todd Adams of Nashville, the recipient of his life-saving gift.
Feb. 5, 2020—Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
Feb. 5, 2020—Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
Jan. 29, 2020—Vanderbilt-Ingram Cancer Center will host a two-day symposium for health care professionals working with rural populations in February.
Jan. 16, 2020—The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.
Jan. 16, 2020—According to a statement on behalf of the American College of Medical Genetics and Genomics, there is insufficient evidence to recommend universal genetic testing for BRCA1/2 alone or in combination with multi-gene panels for all breast cancer patients.
Jan. 9, 2020—Ben Ho Park, MD, PhD, has been named interim director of the Division of Hematology and Oncology.
Jan. 9, 2020—An analysis of weight gain occurring from early to middle adulthood indicates that the added weight is associated with multiple health outcomes in later life.
Dec. 12, 2019—Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.
Dec. 5, 2019—Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.